242 related articles for article (PubMed ID: 31714901)
1. Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease.
Ravell JC; Matsuda-Lennikov M; Chauvin SD; Zou J; Biancalana M; Deeb SJ; Price S; Su HC; Notarangelo G; Jiang P; Morawski A; Kanellopoulou C; Binder K; Mukherjee R; Anibal JT; Sellers B; Zheng L; He T; George AB; Pittaluga S; Powers A; Kleiner DE; Kapuria D; Ghany M; Hunsberger S; Cohen JI; Uzel G; Bergerson J; Wolfe L; Toro C; Gahl W; Folio LR; Matthews H; Angelus P; Chinn IK; Orange JS; Trujillo-Vargas CM; Franco JL; Orrego-Arango J; Gutiérrez-Hincapié S; Patel NC; Raymond K; Patiroglu T; Unal E; Karakukcu M; Day AG; Mehta P; Masutani E; De Ravin SS; Malech HL; Altan-Bonnet G; Rao VK; Mann M; Lenardo MJ
J Clin Invest; 2020 Jan; 130(1):507-522. PubMed ID: 31714901
[TBL] [Abstract][Full Text] [Related]
2. An Update on XMEN Disease.
Ravell JC; Chauvin SD; He T; Lenardo M
J Clin Immunol; 2020 Jul; 40(5):671-681. PubMed ID: 32451662
[TBL] [Abstract][Full Text] [Related]
3. Magnesium transporter 1 (MAGT1) deficiency causes selective defects in
Matsuda-Lennikov M; Biancalana M; Zou J; Ravell JC; Zheng L; Kanellopoulou C; Jiang P; Notarangelo G; Jing H; Masutani E; Oler AJ; Olano LR; Schulz BL; Lenardo MJ
J Biol Chem; 2019 Sep; 294(37):13638-13656. PubMed ID: 31337704
[TBL] [Abstract][Full Text] [Related]
4. MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
Brault J; Meis RJ; Li L; Bello E; Liu T; Sweeney CL; Koontz SM; Dowdell K; Theobald N; Lee J; Allen C; Clark AB; Ravell JC; Lenardo MJ; Dahl GA; Malech HL; De Ravin SS
Cytotherapy; 2021 Mar; 23(3):203-210. PubMed ID: 33051095
[TBL] [Abstract][Full Text] [Related]
5. Diversity of XMEN Disease: Description of 2 Novel Variants and Analysis of the Lymphocyte Phenotype.
Klinken EM; Gray PE; Pillay B; Worley L; Edwards ESJ; Payne K; Bennetts B; Hung D; Wood BA; Chan JJ; Marshall GM; Mitchell R; Uzel G; Ma CS; Tangye SG; McLean-Tooke A
J Clin Immunol; 2020 Feb; 40(2):299-309. PubMed ID: 31865525
[TBL] [Abstract][Full Text] [Related]
6. A Double-Blind, Placebo-Controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Disease.
Chauvin SD; Price S; Zou J; Hunsberger S; Brofferio A; Matthews H; Similuk M; Rosenzweig SD; Su HC; Cohen JI; Lenardo MJ; Ravell JC
J Clin Immunol; 2022 Jan; 42(1):108-118. PubMed ID: 34655400
[TBL] [Abstract][Full Text] [Related]
7. X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia disease: a combined immune deficiency with magnesium defect.
Ravell J; Chaigne-Delalande B; Lenardo M
Curr Opin Pediatr; 2014 Dec; 26(6):713-9. PubMed ID: 25313976
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-targeted MAGT1 insertion restores XMEN patient hematopoietic stem cells and lymphocytes.
Brault J; Liu T; Bello E; Liu S; Sweeney CL; Meis RJ; Koontz S; Corsino C; Choi U; Vayssiere G; Bosticardo M; Dowdell K; Lazzarotto CR; Clark AB; Notarangelo LD; Ravell JC; Lenardo MJ; Kleinstiver BP; Tsai SQ; Wu X; Dahl GA; Malech HL; De Ravin SS
Blood; 2021 Dec; 138(26):2768-2780. PubMed ID: 34086870
[TBL] [Abstract][Full Text] [Related]
9. XMEN: welcome to the glycosphere.
Freeze HH
J Clin Invest; 2020 Jan; 130(1):80-82. PubMed ID: 31815737
[TBL] [Abstract][Full Text] [Related]
10. [X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia: report of a family and literature review].
He TY; Xia Y; Li CG; Li CR; Qi ZX; Yang J
Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):48-52. PubMed ID: 29342998
[No Abstract] [Full Text] [Related]
11. Cutaneous T-cell lymphoma as a unique presenting malignancy in X-linked magnesium defect with EBV infection and neoplasia (XMEN) disease.
Freeman CM; Wright BL; Bauer CS; Rukasin CR; Chiang SC; Marsh RA; Taylor S; Jacobsen J; Miller HK; Badia P
Clin Immunol; 2021 May; 226():108722. PubMed ID: 33831577
[No Abstract] [Full Text] [Related]
12. Adult-onset neurodegeneration in XMEN disease.
Benavides D; Ebrahim A; Ravell JC; Lenardo M; Gahl WA; Toro C
J Neuroimmunol; 2024 Jan; 386():578251. PubMed ID: 38041964
[TBL] [Abstract][Full Text] [Related]
13. Lack of NKG2D in MAGT1-deficient patients is caused by hypoglycosylation.
Blommaert E; Cherepanova NA; Staels F; Wilson MP; Gilmore R; Schrijvers R; Jaeken J; Foulquier F; Matthijs G
Hum Genet; 2022 Jul; 141(7):1279-1286. PubMed ID: 35182234
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease.
Dhalla F; Murray S; Sadler R; Chaigne-Delalande B; Sadaoka T; Soilleux E; Uzel G; Miller J; Collins GP; Hatton CS; Bhole M; Ferry B; Chapel HM; Cohen JI; Patel SY
J Clin Immunol; 2015 Feb; 35(2):112-8. PubMed ID: 25504528
[TBL] [Abstract][Full Text] [Related]
15. MAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation.
Kauskot A; Mallebranche C; Bruneel A; Fenaille F; Solarz J; Viellard T; Feng M; Repérant C; Bordet JC; Cholet S; Denis CV; McCluskey G; Latour S; Martin E; Pellier I; Lasne D; Borgel D; Kracker S; Ziegler A; Tuffigo M; Fournier B; Miot C; Adam F
J Thromb Haemost; 2023 Nov; 21(11):3268-3278. PubMed ID: 37207862
[TBL] [Abstract][Full Text] [Related]
16. Further Delineation of the Spectrum of XMEN Disease in Six Chinese Pediatric Patients.
Peng X; Lu Y; Wang H; Wu B; Gan M; Xu S; Zhuang D; Wang J; Sun J; Wang X; Zhou W
Front Genet; 2022; 13():768000. PubMed ID: 35145548
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel MAGT1 mutation supports a diagnosis of XMEN disease.
Watson CM; Nadat F; Ahmed S; Crinnion LA; O'Riordan S; Carter C; Savic S
Genes Immun; 2022 Apr; 23(2):66-72. PubMed ID: 35264785
[TBL] [Abstract][Full Text] [Related]
18. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D.
Chaigne-Delalande B; Li FY; O'Connor GM; Lukacs MJ; Jiang P; Zheng L; Shatzer A; Biancalana M; Pittaluga S; Matthews HF; Jancel TJ; Bleesing JJ; Marsh RA; Kuijpers TW; Nichols KE; Lucas CL; Nagpal S; Mehmet H; Su HC; Cohen JI; Uzel G; Lenardo MJ
Science; 2013 Jul; 341(6142):186-91. PubMed ID: 23846901
[TBL] [Abstract][Full Text] [Related]
19. CD5 B-Cell Predominant Primary Immunodeficiency: Part of the Spectrum of
Rowane MJ; Stewart-Bates BC; Doll RJ; Meyerson HJ; Venglarcik JS; Callahan M; Fill L; Saab R; Ochs HD; Hostoffer RW
Ther Adv Allergy Rhinol; 2023; 14():27534030231199675. PubMed ID: 37706151
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease.
Ding H; Li Y; Fang M; Chen J; Liu L; Lu Z; Hou J; Luo M
J Allergy Clin Immunol; 2023 Jun; 151(6):1622-1633.e10. PubMed ID: 37086924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
